|
40 Companies |
|
51 Products |
|
51 Products |
|
0 Mechanisms of Action |
|
20 Trials |
|
425 News |
|
| «12345678» |
- || Clotinab (abciximab) / ISU Abxis
Trial primary completion date: Abciximab (ReoPro) as a Therapeutic Intervention for Sickle Cell Vaso-Occlusive Pain Crisis (clinicaltrials.gov) - Sep 4, 2014
P2, N=100, Recruiting, Sponsor: St. Louis University
Trial primary completion date: Nov 2015 --> Mar 2016
- Clinical: Working Memory and School Readiness in Preschool-Aged Children With Sickle Cell Disease (clinicaltrials.gov) - Aug 29, 2014
P=N/A, N=99, Not yet recruiting, Sponsor: St. Jude Children's Research Hospital
- Clinical: Fertility Preservation in Women Who Will Have Gonadotoxic Therapy or Hematopoetic Stem Cell Transplantation, and in Women With Sickle Cell Disease (clinicaltrials.gov) - Aug 26, 2014
P=N/A, N=10, Recruiting, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- | morphine sulphate / Generic mfg., hydromorphone hydrochloride / Generic mfg.
New P4 trial: Comparing Acute Pain Management Protocols for Patients With Sickle Cell Disease (clinicaltrials.gov) - Aug 21, 2014
P4, N=77, Not yet recruiting, Sponsor: Duke University
- Trial completion, Enrollment change: Cognitive Rehabilitation in Sickle Cell Disease (clinicaltrials.gov) - Aug 21, 2014
P=N/A, N=18, Completed, Sponsor: Duke University
Trial primary completion date: Nov 2015 --> Mar 2016 Recruiting --> Completed | N=30 --> 18
- decitabine / Generic mfg.
Trial primary completion date: Decitabine for High-Risk Sickle Cell Disease (clinicaltrials.gov) - Aug 19, 2014
P2, N=40, Recruiting, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting --> Completed | N=30 --> 18 Trial primary completion date: Dec 2016 --> Dec 2015
- | ticagrelor / Generic mfg.
New P2 trial: HESTIA 1: A Pharmacokinetic (PK) and Pharmacodynamic (PD) Dose-ranging Phase II Study of Ticagrelor in Paediatric Patients With Sickle Cell Disease (clinicaltrials.gov) - Aug 12, 2014
P2, N=49, Not yet recruiting, Sponsor: AstraZeneca
- plerixafor / Generic mfg.
New P1/2 trial: DrepaMob: Assessment of Tolerance of Mobilizing Peripheral Hematopoietic Stem Cells by Plerixafor in Sickle Cell Patients (clinicaltrials.gov) - Aug 8, 2014
P1/2, N=5, Not yet recruiting, Sponsor: Assistance Publique - H
- hydroxyurea / Generic mfg.
Trial primary completion date: State Of The Art Functional Imaging In Sickle Cell Disease (clinicaltrials.gov) - Aug 7, 2014
P=N/A, N=60, Recruiting, Sponsor: St. Jude Children's Research Hospital
Trial primary completion date: Dec 2016 --> Dec 2015 Trial primary completion date: Dec 2014 --> Dec 2015
- Trial completion: Dr (clinicaltrials.gov) - Aug 6, 2014
P=N/A, N=160, Completed, Sponsor: Fondation Ophtalmologique Adolphe de Rothschild
Trial primary completion date: Dec 2014 --> Dec 2015 Recruiting --> Completed
- Enrollment open, Adherence: Medication Adherence in Youth With Sickle Cell Disease (SCD) (clinicaltrials.gov) - Aug 4, 2014
P=N/A, N=60, Recruiting, Sponsor: St. Jude Children's Research Hospital
Recruiting --> Completed Not yet recruiting --> Recruiting
- propranolol / Generic mfg.
Trial completion, Trial primary completion date: Study of Propranolol as Anti-Adhesive Therapy in Sickle Cell Disease (SCD) (clinicaltrials.gov) - Aug 1, 2014
P2, N=27, Completed, Sponsor: Laura M. De Castro, MD
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial primary completion date: Mar 2013 --> Dec 2013
- || Enrollment closed, Enrollment change, Trial primary completion date: SUFEMYO: Multicenter Observational Study on Myocardial Iron Overload in 3 Multitransfused Populations (clinicaltrials.gov) - Jul 28, 2014
P=N/A, N=110, Active, not recruiting, Sponsor: Assistance Publique - H
Active, not recruiting --> Completed | Trial primary completion date: Mar 2013 --> Dec 2013 Recruiting --> Active, not recruiting | N=210 --> 110 | Trial primary completion date: Mar 2014 --> Oct 2014
- Clinical: iTransition: Patient-Provider Tools to Improve the Transition to Adult Care in Sickle Cell Disease (clinicaltrials.gov) - Jul 27, 2014
P=N/A, N=85, Enrolling by invitation, Sponsor: Children's Hospital Medical Center, Cincinnati
- Trial termination: Inhaled Nitric Oxide for Pediatric Painful Sickle Crisis (clinicaltrials.gov) - Jul 23, 2014
P2, N=18, Terminated, Sponsor: Children's Hospital Boston
Recruiting --> Active, not recruiting | N=210 --> 110 | Trial primary completion date: Mar 2014 --> Oct 2014 Recruiting --> Terminated; 18 or 20 enrolled, stopped due to paucity of available participants
- | Trial completion: SIT: Silent Cerebral Infarct Transfusion Multi-Center Clinical Trial (clinicaltrials.gov) - Jul 16, 2014
P3, N=196, Completed, Sponsor: Washington University School of Medicine
Recruiting --> Terminated; 18 or 20 enrolled, stopped due to paucity of available participants Active, not recruiting --> Completed
- deferiprone / Generic mfg.
Trial completion, Trial primary completion date: Absorption, Metabolism, and Excretion of a Single Dose of Ferriprox (clinicaltrials.gov) - Jul 14, 2014
P1, N=8, Completed, Sponsor: ApoPharma
Active, not recruiting --> Completed Not yet recruiting --> Completed | Trial primary completion date: Jul 2013 --> Apr 2014
- budesonide inhalation suspension / Generic mfg.
New P1 trial: Inhaled Corticosteroid Use to Prevent Acute Chest Syndrome Recurrence in Children Between 1 and 4 With Sickle Cell Disease: a Feasibility Trial (clinicaltrials.gov) - Jul 12, 2014
P1, N=20, Recruiting, Sponsor: Vanderbilt University
- Enrollment closed: The Brigance Assessment Of Individual Neurodevelopment In Young Children With Sickle Cell Disease- 2 (clinicaltrials.gov) - Jul 12, 2014
P=N/A, N=272, Active, not recruiting, Sponsor: St. Jude Children's Research Hospital
Not yet recruiting --> Completed | Trial primary completion date: Jul 2013 --> Apr 2014 Recruiting --> Active, not recruiting
- Trial primary completion date: Serum Brain Natriuretic Peptide Levels and Pulmonary Hypertension in Pediatric Sickle Cell Patients (clinicaltrials.gov) - Jun 27, 2014
P=N/A, N=21, Completed, Sponsor: Akron Children's Hospital
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2012 --> Jun 2013
- Enrollment change: Adolescent, Caregiver, and Young Adult Perspectives of the Transition From Pediatric to Adult Care for Sickle Cell Disease: A Preliminary Evaluation of the Sickle Cell Disease Transition Program (clinicaltrials.gov) - Jun 27, 2014
P=N/A, N=55, Completed, Sponsor: St. Jude Children's Research Hospital
Trial primary completion date: Dec 2012 --> Jun 2013 N=72 --> 55
- Trial completion, Enrollment change: Adolescent, Caregiver, and Young Adult Perspectives of the Transition From Pediatric to Adult Care for Sickle Cell Disease: A Preliminary Evaluation of the Sickle Cell Disease Transition Program (clinicaltrials.gov) - Jun 27, 2014
P=N/A, N=55, Completed, Sponsor: St. Jude Children's Research Hospital
N=72 --> 55 Recruiting --> Completed | N=72 --> 55
- Trial completion, Trial primary completion date: Serum Brain Natriuretic Peptide Levels and Pulmonary Hypertension in Pediatric Sickle Cell Patients (clinicaltrials.gov) - Jun 27, 2014
P=N/A, N=21, Completed, Sponsor: Akron Children's Hospital
Recruiting --> Completed | N=72 --> 55 Enrolling by invitation --> Completed | Trial primary completion date: Dec 2012 --> Jun 2013
- Enrollment open: IMPROVE: Inhaled Mometasone to Reduce Painful Episodes in Patients With Sickle Cell Disease (clinicaltrials.gov) - Jun 19, 2014
P2, N=45, Recruiting, Sponsor: Jeffrey Glassberg
Enrolling by invitation --> Completed | Trial primary completion date: Dec 2012 --> Jun 2013 Not yet recruiting --> Recruiting
- Zyflo (zileuton) / Chiesi
Trial completion: Trial of Zileuton CR in Children and Adults With Sickle Cell Disease (clinicaltrials.gov) - Jun 19, 2014
P1, N=9, Completed, Sponsor: Children's Hospital Medical Center, Cincinnati
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- New P2 trial: Study of Beet Juice for Patients With Sickle Cell Anemia (clinicaltrials.gov) - Jun 13, 2014
P2, N=24, Not yet recruiting, Sponsor: Daniel Kim-Shapiro
- Trial primary completion date: Carbon Monoxide Monitor for the Measurement of End-Tidal Carbon Monoxide Levels in Children With or Without Hemolysis (clinicaltrials.gov) - May 28, 2014
P=N/A, N=40, Completed, Sponsor: Ashutosh Lal
Active, not recruiting --> Completed Trial primary completion date: Dec 2013 --> Mar 2014
- Trial completion: Carbon Monoxide Monitor for the Measurement of End-Tidal Carbon Monoxide Levels in Children With or Without Hemolysis (clinicaltrials.gov) - May 28, 2014
P=N/A, N=40, Completed, Sponsor: Ashutosh Lal
Trial primary completion date: Dec 2013 --> Mar 2014 Recruiting --> Completed
- hydroxyurea / Generic mfg.
Trial completion date: SCD_Cross: Curative Versus Disease-Modifying Therapies in Children With Severe Sickle Cell Disease (clinicaltrials.gov) - May 22, 2014
P=N/A, N=33, Completed, Sponsor: Emory University
Recruiting --> Completed Trial completion date: May 2007 --> Mar 2014
- Trial primary completion date: Analysis of T-Cell Immune Reconstitution Following Allogeneic Hematopoietic BMT for Severe SCD (clinicaltrials.gov) - May 22, 2014
P=N/A, N=7, Completed, Sponsor: Emory University
Trial completion date: May 2007 --> Mar 2014 Trial primary completion date: Sep 2015 --> Aug 2011
- Trial completion date: Analysis of T-Cell Immune Reconstitution Following Allogeneic Hematopoietic BMT for Severe SCD (clinicaltrials.gov) - May 22, 2014
P=N/A, N=7, Completed, Sponsor: Emory University
Trial primary completion date: Sep 2015 --> Aug 2011 Trial completion date: Sep 2017 --> Jul 2012
- Enrollment change: Analysis of T-Cell Immune Reconstitution Following Allogeneic Hematopoietic BMT for Severe SCD (clinicaltrials.gov) - May 22, 2014
P=N/A, N=7, Completed, Sponsor: Emory University
Trial completion date: Sep 2017 --> Jul 2012 N=20 --> 7
- Trial completion: Analysis of T-Cell Immune Reconstitution Following Allogeneic Hematopoietic BMT for Severe SCD (clinicaltrials.gov) - May 22, 2014
P=N/A, N=7, Completed, Sponsor: Emory University
N=20 --> 7 Recruiting --> Completed
- Zyflo (zileuton) / Chiesi
Trial completion date: Trial of Zileuton CR in Children and Adults With Sickle Cell Disease (clinicaltrials.gov) - May 21, 2014
P1, N=9, Active, not recruiting, Sponsor: Children's Hospital Medical Center, Cincinnati
Recruiting --> Completed Trial completion date: Dec 2013 --> Dec 2014
- Adherence: Medication Adherence in Youth With Sickle Cell Disease (SCD) (clinicaltrials.gov) - May 18, 2014
P=N/A, N=60, Not yet recruiting, Sponsor: St. Jude Children's Research Hospital
- Trial primary completion date: Topical Sodium Nitrite for Chronic Leg Ulcers in Adult Patients With Blood Disorders (clinicaltrials.gov) - May 2, 2014
P1, N=44, Recruiting, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Trial completion date: Dec 2013 --> Dec 2014 Trial primary completion date: Jun 2013 --> Apr 2015
- Trial completion date: Topical Sodium Nitrite for Chronic Leg Ulcers in Adult Patients With Blood Disorders (clinicaltrials.gov) - May 2, 2014
P1, N=44, Recruiting, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Trial primary completion date: Jun 2013 --> Apr 2015 Trial completion date: Jun 2014 --> Apr 2015
- Enrollment open: Topical Sodium Nitrite for Chronic Leg Ulcers in Adult Patients With Blood Disorders (clinicaltrials.gov) - May 2, 2014
P1, N=44, Recruiting, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Trial completion date: Jun 2014 --> Apr 2015 Active, not recruiting --> Recruiting
- Enrollment change: Topical Sodium Nitrite for Chronic Leg Ulcers in Adult Patients With Blood Disorders (clinicaltrials.gov) - May 2, 2014
P1, N=23, Active, not recruiting, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Active, not recruiting --> Recruiting N=18 --> 23
- | Enrollment open: SOMMEDREP: Sleep Respiratory Disorders Evaluation in Sickle Cell Disease Children (clinicaltrials.gov) - Apr 27, 2014
P2/3, N=280, Recruiting, Sponsor: Assistance Publique - H
N=18 --> 23 Not yet recruiting --> Recruiting
- Clinical: PArTNER: PATient Navigator to rEduce Readmissions (clinicaltrials.gov) - Apr 13, 2014
P=N/A, N=1130, Not yet recruiting, Sponsor: University of Illinois at Chicago
- ||| PF-04447943 / Pfizer
New P1 trial: Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Study Of PF-04447943, Co-Administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease (clinicaltrials.gov) - Apr 13, 2014
P1, N=64, Not yet recruiting, Sponsor: Pfizer
- Enrollment open: Quantifying the Presence of Lung Disease and Pulmonary Hypertension in Children With Sickle Cell Disease (clinicaltrials.gov) - Apr 7, 2014
P1, N=32, Recruiting, Sponsor: Duke University
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Mefliam Plus (artesunate/mefloquine) / Cipla, Oswaldo Cruz Foundation, DNDi
Trial completion: Intermittent Preventive Treatment for Malaria in Patient With Sickle Cell Disease (clinicaltrials.gov) - Mar 19, 2014
P1/2, N=270, Completed, Sponsor: London School of Hygiene and Tropical Medicine
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- hydroxyurea / Generic mfg.
New P2 trial: Risk-based Therapy for Sickle Cell Anemia: A Feasibility Study (clinicaltrials.gov) - Mar 16, 2014
P2, N=48, Recruiting, Sponsor: Children's Research Institute
- fludarabine IV / Generic mfg., cyclophosphamide / Generic mfg.
Trial suspension: Sickle Cell Disease Conditioning for Bone Marrow Transplant (clinicaltrials.gov) - Mar 8, 2014
P1, N=24, Suspended, Sponsor: Emory University
Active, not recruiting --> Completed Recruiting --> Suspended
- | montelukast / Generic mfg.
Enrollment open: Phase 2 Study of Montelukast for the Treatment of Sickle Cell Anemia (clinicaltrials.gov) - Mar 5, 2014
P2, N=63, Recruiting, Sponsor: Vanderbilt University
Recruiting --> Suspended Not yet recruiting --> Recruiting
- Enrollment change: Microvessels and Heart Problems in Sickle Cell Disease (clinicaltrials.gov) - Feb 26, 2014
P=N/A, N=85, Recruiting, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Not yet recruiting --> Recruiting N=70 --> 85
- Enrollment closed: RAND: Albuminuria Reduction With Renin Angiotensin System Inhibitors in SCA Patients (clinicaltrials.gov) - Feb 25, 2014
P=N/A, N=53, Active, not recruiting, Sponsor: Assistance Publique - H
N=70 --> 85 Recruiting --> Active, not recruiting
- |||| deferoxamine / Generic mfg.
Trial completion: Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients (clinicaltrials.gov) - Feb 22, 2014
P2, N=212, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Active, not recruiting --> Completed